US20030040541A1 - Use of bismuth subgallate in inhibition of production of nitric oxide synthase - Google Patents
Use of bismuth subgallate in inhibition of production of nitric oxide synthase Download PDFInfo
- Publication number
- US20030040541A1 US20030040541A1 US10/075,040 US7504002A US2003040541A1 US 20030040541 A1 US20030040541 A1 US 20030040541A1 US 7504002 A US7504002 A US 7504002A US 2003040541 A1 US2003040541 A1 US 2003040541A1
- Authority
- US
- United States
- Prior art keywords
- production
- pharmaceutical composition
- bismuth subgallate
- disease
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/245—Bismuth; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to a new use of bismuth subgallate in the inhibition of the production of nitric oxide synthase.
- Nitric oxide is an unstable free radical that mediates both homeostatic and pathophysiologic processes within the cardiopulmonary, nervous, and immune systems.
- the list of potential disease associations for NO is increasing dramatically (Cochran et al., Medicinal Research Reviews, 1996, 16(6):547-563).
- agents that modulate the activity of NO may be of considerable therapeutic value.
- those that reduce the formation of NO may be beneficial in pathophysiological states in which excessive production of NO is a contributory factor. These include diseases such as septic shock, neurodegenerative disorders, and inflammation.
- NO is formed endogenously by a family of enzymes known as nitric oxide synthases (NOS) (Hobbs et al., Annu. Rev. Pharmacol. Toxicol, 1999, 39:191-220).
- NOS inducible form
- nNOS neuronal NOS
- eNOS endothelial NOS
- U.S. Pat. No. 6,030,985 discloses the amidine derivatives useful for treating and preventing conditions in which inhibition of nitric oxide synthase is beneficial, such as stroke, schizophrenia, anxiety, and pain.
- U.S. Pat. No. 6,071,906 provides a pharmaceutical compositions containing an amidino derivative useful as an inhibitor of nitric oxide synthase.
- U.S. Pat. No. 6,133,306 features treating a neurodegenerative disease by administration of an effective amount of a nitroindazole, which is an inhibitor of neuronal nitric oxide synthase.
- No. 6,235,747 relates to certain 6-phenyl-pyridin-2-ylamine derivatives that exhibit activity as nitric oxide synthase (NOS) inhibitors, to pharmaceutical compositions containing them and to their use in the treatment and prevention of central nervous system disorders.
- NOS nitric oxide synthase
- Bismuth subgallate is the product of the reaction among gallic acid, glacial acetic acid and bismuth nitrate which is represented by a chemical formula of C 7 H 5 BiO 6 . It is known as an oral anti-diarrhea agent effective in treating acute or chronic diarrhea by virtue that it can react with H 2 S, which is present in large quantities in the intestinal tract due to abnormal fermentation, and thereby alleviate diarrhea and pains caused by gas irritation to the intestinal tract. Bismuth subgallate can also be used as a disinfectant in view of its nature as a benzene derivative.
- a pharmaceutical composition for wound healing comprising bismuth subgallate and borneol is disclosed in U.S. Pat. No. 6,232,341.
- none of the prior art teaches or suggests the new use of bismuth subgallate in the inhibition of NO synthase.
- the invention provides the new use of bismuth subgallate in the inhibition of the production of NOS.
- An object of the invention is to provide a method of inhibiting the production of nitric oxide synthases (NOS) in a subject, comprising administering to said subject in need thereof an effective amount of bismuth subgallate; wherein said bismuth subgallate is administered in an amount effective to inhibit the production of NOS.
- the method comprises administering to said subject in need thereof an effective amount of bismuth subgallate in combination with borneol, wherein said bismuth subgallate in combination with borneol are administered in an amount synergistically effective to inhibit the production of NOS.
- Another objective of the invention is to provide a pharmaceutical composition for inhibiting the production of nitric oxide synthases comprising an effective amount of bismuth subgallate sufficient to inhibit the production of NOS and a pharmaceutical acceptable carrier.
- the pharmaceutical composition of the invention further comprises borneol to provide a synergistic effect in the inhibition of the production of NOS.
- FIG. 1 shows the effect of bismuth subgallate on NO production by the activated RAW 264.7 cells.
- FIG. 2 shows the effect of borneol on NO production by the activated RAW 264.7 cells.
- FIG. 3 shows the effect of bismuth subgallate in combination with borneol on NO production by the activated RAW 264.7 cells.
- the present invention relates to a new use of bismuth subgallate in the inhibition of the production of nitric oxide synthases. It is surprisingly found in the invention that bismuth subgallate is useful in the inhibition of the production of nitric oxide synthase.
- the claimed invention provides a method of inhibiting the production of nitric oxide synthases (NOS) in a subject, comprising administering to said subject in need thereof an effective amount of bismuth subgallate, wherein said bismuth subgallate is administered in an amount effective to inhibit the production of NOS.
- NOS nitric oxide synthases
- the claimed invention provides a method of inhibiting the production of nitric oxide synthases (NOS) in a subject, comprising administering to said subject in need thereof an synergistically effective amount of bismuth subgallate in combination with borneol, wherein said bismuth subgallate in combination with borneol are administered in an amount synergistically effective to inhibit the production of NOS.
- NOS nitric oxide synthases
- bismuth subgallate refers to the product of the reaction among gallic acid, glacial acetic acid and bismuth nitrate which is represented by a chemical formula of C 7 H 5 BiO 6 .
- borneol refers to the product isolated from Dryobalanops aromatica or the like and represented by the chemical formula C 10 H 17 OH.
- the term “effective amount” as used herein refers to an amount sufficient to provide an effect sufficient for the inhibition of the production of nitric oxide synthases to bring improvement in patients.
- carrier refers to a diluent, an excipient, a recipient and the like for use in preparing admixtures of a pharmaceutical composition.
- the invention provides a pharmaceutical composition for use in the inhibition of the production of nitric oxide synthase, which comprises an effective amount of bismuth subgallate sufficient to inhibit the production of NOS and a pharmaceutical acceptable carrier.
- the pharmaceutical composition preferably comprises bismuth subgallate at an amount ranging from 0.05 to 40 percent by weight. More preferably, the amount of bismuth subgallate in the pharmaceutical composition according to the present invention is from 1 to 20 percent by weight. Most preferably, the amount of bismuth subgallate in the topical pharmaceutical composition according to the present invention is from 2 to 10 percent by weight.
- the pharmaceutical composition further comprising borneol is synergistically effective in the inhibition of nitric oxide synthases.
- the pharmaceutical composition comprises bismuth subgallate at an amount ranging from 1 to 30 percent by weight and borneol at an amount ranging from 0.05 to 10 percent by weight. More preferably, the amounts of bismuth subgallate and borneol in the pharmaceutical composition are from 3 to 15 percent by weight, and from 0.1 to 5 percent by weight, respectively. Most preferably, the amounts of bismuth subgallate and borneol in the pharmaceutical composition are from 4 to 8 percent by weight and from 0.5 to 1 percent by weight, respectively.
- the pharmaceutical composition according to the present invention may further comprise other traditional agents which are helpful in the inhibition of nitric oxide synthases, such as the compounds disclosed in WO 94/12165, WO 94/14780, WO 93/13055, EP 0446699A1, U.S. Pat. No. 5,132,453, U.S. Pat. No. 6,030,985, U.S. Pat. No. 6,071,906, U.S. Pat. No. 6,133,306 and U.S. Pat. No. 6,235,747.
- the incorporation of these traditional agents into the pharmaceutical composition according to the present invention is readily available for ordinary persons skilled in the art.
- suitable doses of the pharmaceutical composition according to the invention may be determined routinely by the medical practitioner or other skilled persons, and include the respective doses discussed in the prior art disclosing bismuth subgallate and borneol that are mentioned hereinbefore. The disclosures are hereby incorporated by reference.
- a physician or a skilled person, will be able to determine the actual dosage which will be most suitable for an individual patient.
- the dosage is likely to vary depending on the condition that is to be treated, as well as the age, weight, sex and response of the particular patient to be treated.
- the pharmaceutical composition can be formulated for topical, oral, parenteral or other mode of administration.
- suitable pharmaceutical carriers used in the pharmaceutical composition of the invention include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, gelatin, carbohydrates (such as lactose, amylose or starch), magnesium stearate, talc, silicic acid, viscous paraffin, fatty acid esters, hydroxymethylcellulose, polyvinyl pyrrolidone, etc.
- Injectable, sterile solutions preferably oily or aqueous solutions, as well as suspensions, emulsions, or implants, including suppositories are particularly suitable for parenteral application.
- Ampoules are convenient unit dosages.
- Oral applications are preferably administered in the forms of capsules, tablets and/or liquid formulations.
- the pharmaceutical composition of the invention is preferably administered in the forms of paste, cream and gel paste etc. More preferably, the pharmaceutical composition may further comprise anti-inflammatory agents, astringents, emollients or analgesics.
- the pharmaceutical composition can be used in the inhibition of the production of nitric oxide synthase. Therefore, the pharmaceutical composition is effective in the treatment of the diseases in which nitric oxide production is implicated, such as platelet aggregation deficiency, homeostatic process disorder, tissue injury, migraine, inflammatory diseases (e.g., asthma), stroke, acute and chronic pain, hypovolemic shock, traumatic shock, reperfusion injury, Crohn's disease, ulcerative colitis, septic shock, multiple sclerosis, AIDS associated dementia, neurodegenerative diseases, neuron toxicity, Alzheimer's disease, chemical dependencies and addictions (e.g., dependencies on drugs, alcohol and nicotine), emesis, epilepsy, anxiety, psychosis, head trauma, adult respiratory distress syndrome (ARDS), morphine induced tolerance and withdrawal symptoms, inflammatory bowel disease, osteoarthritis, rheumatoid arthritis, dilated cardiomyopathy, acute spinal cord injury, Huntington's disease, Parkinson's
- the pharmaceutical composition of the invention is useful in treating the conditions associated with platelet aggregation, homeostatic processes and tissue injury.
- the treatment of the condition of platelet aggregation has the effect on rapid hemostasis.
- mice macrophage cell line RAW 264.7 (under accession number CCRC 60001), which was obtained from Cell Culture Research Center, Food Industry Research and Development Institute, Hsinchu, Taiwan, R.O.C., were used for the test.
- the RAW 264.7 cells were incubated in a 96 well tissue culture plate (Falcon). After 24 hours, the cells were activated with Dulbecco's Modified Eagle Medium (DMEM, 2014, GibcoBRL) in the presence and absence of 100 ng/ml LPS, 100 U/ml IFN- ⁇ and various concentrations (10 ⁇ M, 20 ⁇ M, 50 ⁇ M, 100 ⁇ M and 200 ⁇ M) of bismuth subgallate (Hwang et al., 1994, J. Biol. Chem. 269, p. 711-715).
- DMEM Dulbecco's Modified Eagle Medium
- the cells, which were not activated, by LPS and IFN- ⁇ did not produce NO.
- the cells, which were activated, by LPS and IFN- ⁇ produced up to 65 ⁇ M of NO.
- those from cells incubated in the presence of bismuth subgallate showed a reduction in nitrite concentration, reflecting the reduction in NO production.
- the production of NO was inversely proportional to the increase in the concentration of bismuth subgallate.
Abstract
The present invention discloses the new use of bismuth subgallate for use in the inhibition of the production of nitric oxide synthase. Also disclosed is the synergistic efficacy of bismuth subgallate in combination with borneol in the inhibition of the production of nitric oxide synthase.
Description
- 1. Field of the Invention
- The present invention relates to a new use of bismuth subgallate in the inhibition of the production of nitric oxide synthase.
- 2. Description of the Prior Art
- Nitric oxide (NO) is an unstable free radical that mediates both homeostatic and pathophysiologic processes within the cardiopulmonary, nervous, and immune systems. The list of potential disease associations for NO is increasing dramatically (Cochran et al.,Medicinal Research Reviews, 1996, 16(6):547-563). Thus, agents that modulate the activity of NO may be of considerable therapeutic value. In particular, those that reduce the formation of NO may be beneficial in pathophysiological states in which excessive production of NO is a contributory factor. These include diseases such as septic shock, neurodegenerative disorders, and inflammation. NO is formed endogenously by a family of enzymes known as nitric oxide synthases (NOS) (Hobbs et al., Annu. Rev. Pharmacol. Toxicol, 1999, 39:191-220).
- It is known that three distinct isoforms of NOS have been identified: an inducible form (iNOS) and two constitutive forms referred to neuronal NOS (nNOS) and endothelial NOS (eNOS). The NOS, particularly iNOS, are associated with the conditions including platelet aggregation, homeostatic processes, tissue injury, inflammatory conditions, shock states, immune disorders, disorders of gastrointestinal motility and diseases of the central and peripheral nervous system and diabetes (Epstein,The New England Journal of Medicine, 1993, 329(27): 2002-2011; Hobbs. et al, Annu. Rev. Pharmacol. Toxicol., 1999, 39: 191-220; Pfeilschfter et al, Cell Biology International, 1996, 20(1): 51-58). It is believed that neuropathy is closely related to diabetic ulcers and thus the neuropathy is a major contributing factor to most lower extremity diabetic ulcers (N. Engl J Med, Volume 343 (11), Sep. 14, 2000, pp. 787-793; and J. Fam. Pract., Volume 49(11) Supplement, November 2000, pp. S40-S48). The NOSs are also associated with the conditions caused by nitric oxide, such as tissue injury, cerebral ischemia, epilepsy, immunity and inflammation (Mulligan et al., Proc. Natl. Acad. Sci. USA, 1991, 88:6338-6342).
- Given the above, it is expected that the compounds or agents capable of decreasing the amount or activity of NOS are useful as therapeutic agents. For example, U.S. Pat. No. 6,030,985 discloses the amidine derivatives useful for treating and preventing conditions in which inhibition of nitric oxide synthase is beneficial, such as stroke, schizophrenia, anxiety, and pain. U.S. Pat. No. 6,071,906 provides a pharmaceutical compositions containing an amidino derivative useful as an inhibitor of nitric oxide synthase. U.S. Pat. No. 6,133,306 features treating a neurodegenerative disease by administration of an effective amount of a nitroindazole, which is an inhibitor of neuronal nitric oxide synthase. U.S. Pat. No. 6,235,747 relates to certain 6-phenyl-pyridin-2-ylamine derivatives that exhibit activity as nitric oxide synthase (NOS) inhibitors, to pharmaceutical compositions containing them and to their use in the treatment and prevention of central nervous system disorders.
- Bismuth subgallate is the product of the reaction among gallic acid, glacial acetic acid and bismuth nitrate which is represented by a chemical formula of C7H5BiO6. It is known as an oral anti-diarrhea agent effective in treating acute or chronic diarrhea by virtue that it can react with H2S, which is present in large quantities in the intestinal tract due to abnormal fermentation, and thereby alleviate diarrhea and pains caused by gas irritation to the intestinal tract. Bismuth subgallate can also be used as a disinfectant in view of its nature as a benzene derivative.
- A pharmaceutical composition for wound healing comprising bismuth subgallate and borneol is disclosed in U.S. Pat. No. 6,232,341. However, none of the prior art teaches or suggests the new use of bismuth subgallate in the inhibition of NO synthase.
- It is surprisingly found that bismuth subgallate is useful in the inhibition of the production of nitric oxide synthase (NOS).
- Accordingly, the invention provides the new use of bismuth subgallate in the inhibition of the production of NOS.
- An object of the invention is to provide a method of inhibiting the production of nitric oxide synthases (NOS) in a subject, comprising administering to said subject in need thereof an effective amount of bismuth subgallate; wherein said bismuth subgallate is administered in an amount effective to inhibit the production of NOS. According to the preferred embodiment of the invention, the method comprises administering to said subject in need thereof an effective amount of bismuth subgallate in combination with borneol, wherein said bismuth subgallate in combination with borneol are administered in an amount synergistically effective to inhibit the production of NOS.
- Another objective of the invention is to provide a pharmaceutical composition for inhibiting the production of nitric oxide synthases comprising an effective amount of bismuth subgallate sufficient to inhibit the production of NOS and a pharmaceutical acceptable carrier. According to a preferred embodiment of the invention, the pharmaceutical composition of the invention further comprises borneol to provide a synergistic effect in the inhibition of the production of NOS.
- FIG. 1 shows the effect of bismuth subgallate on NO production by the activated RAW 264.7 cells.
- FIG. 2 shows the effect of borneol on NO production by the activated RAW 264.7 cells.
- FIG. 3 shows the effect of bismuth subgallate in combination with borneol on NO production by the activated RAW 264.7 cells.
- The present invention relates to a new use of bismuth subgallate in the inhibition of the production of nitric oxide synthases. It is surprisingly found in the invention that bismuth subgallate is useful in the inhibition of the production of nitric oxide synthase. In particular, the claimed invention provides a method of inhibiting the production of nitric oxide synthases (NOS) in a subject, comprising administering to said subject in need thereof an effective amount of bismuth subgallate, wherein said bismuth subgallate is administered in an amount effective to inhibit the production of NOS. In addition, it is found that bismuth subgallate in combination with borneol exhibit a synergistic effect in the inhibition of the production of nitric oxide synthase. In particular, the claimed invention provides a method of inhibiting the production of nitric oxide synthases (NOS) in a subject, comprising administering to said subject in need thereof an synergistically effective amount of bismuth subgallate in combination with borneol, wherein said bismuth subgallate in combination with borneol are administered in an amount synergistically effective to inhibit the production of NOS.
- Definition
- The term “bismuth subgallate” as used herein, refers to the product of the reaction among gallic acid, glacial acetic acid and bismuth nitrate which is represented by a chemical formula of C7H5BiO6.
- The term “borneol” as used herein, refers to the product isolated from Dryobalanops aromatica or the like and represented by the chemical formula C10H17OH.
- The term “effective amount” as used herein refers to an amount sufficient to provide an effect sufficient for the inhibition of the production of nitric oxide synthases to bring improvement in patients.
- The term “carrier” as used herein refers to a diluent, an excipient, a recipient and the like for use in preparing admixtures of a pharmaceutical composition.
- Pharmaceutical Composition
- The invention provides a pharmaceutical composition for use in the inhibition of the production of nitric oxide synthase, which comprises an effective amount of bismuth subgallate sufficient to inhibit the production of NOS and a pharmaceutical acceptable carrier.
- The pharmaceutical composition preferably comprises bismuth subgallate at an amount ranging from 0.05 to 40 percent by weight. More preferably, the amount of bismuth subgallate in the pharmaceutical composition according to the present invention is from 1 to 20 percent by weight. Most preferably, the amount of bismuth subgallate in the topical pharmaceutical composition according to the present invention is from 2 to 10 percent by weight.
- According to the invention, the pharmaceutical composition further comprising borneol is synergistically effective in the inhibition of nitric oxide synthases. Preferably, the pharmaceutical composition comprises bismuth subgallate at an amount ranging from 1 to 30 percent by weight and borneol at an amount ranging from 0.05 to 10 percent by weight. More preferably, the amounts of bismuth subgallate and borneol in the pharmaceutical composition are from 3 to 15 percent by weight, and from 0.1 to 5 percent by weight, respectively. Most preferably, the amounts of bismuth subgallate and borneol in the pharmaceutical composition are from 4 to 8 percent by weight and from 0.5 to 1 percent by weight, respectively.
- Apart from the above-mentioned active ingredients, the pharmaceutical composition according to the present invention may further comprise other traditional agents which are helpful in the inhibition of nitric oxide synthases, such as the compounds disclosed in WO 94/12165, WO 94/14780, WO 93/13055, EP 0446699A1, U.S. Pat. No. 5,132,453, U.S. Pat. No. 6,030,985, U.S. Pat. No. 6,071,906, U.S. Pat. No. 6,133,306 and U.S. Pat. No. 6,235,747. The incorporation of these traditional agents into the pharmaceutical composition according to the present invention is readily available for ordinary persons skilled in the art.
- According to the invention, suitable doses of the pharmaceutical composition according to the invention may be determined routinely by the medical practitioner or other skilled persons, and include the respective doses discussed in the prior art disclosing bismuth subgallate and borneol that are mentioned hereinbefore. The disclosures are hereby incorporated by reference.
- In any event, a physician, or a skilled person, will be able to determine the actual dosage which will be most suitable for an individual patient. The dosage is likely to vary depending on the condition that is to be treated, as well as the age, weight, sex and response of the particular patient to be treated.
- According to the invention, the pharmaceutical composition can be formulated for topical, oral, parenteral or other mode of administration. Suitable pharmaceutical carriers used in the pharmaceutical composition of the invention include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, gelatin, carbohydrates (such as lactose, amylose or starch), magnesium stearate, talc, silicic acid, viscous paraffin, fatty acid esters, hydroxymethylcellulose, polyvinyl pyrrolidone, etc.
- Injectable, sterile solutions, preferably oily or aqueous solutions, as well as suspensions, emulsions, or implants, including suppositories are particularly suitable for parenteral application. Ampoules are convenient unit dosages. Oral applications are preferably administered in the forms of capsules, tablets and/or liquid formulations.
- For topical applications, the pharmaceutical composition of the invention is preferably administered in the forms of paste, cream and gel paste etc. More preferably, the pharmaceutical composition may further comprise anti-inflammatory agents, astringents, emollients or analgesics.
- Utility
- According to the invention, the pharmaceutical composition can be used in the inhibition of the production of nitric oxide synthase. Therefore, the pharmaceutical composition is effective in the treatment of the diseases in which nitric oxide production is implicated, such as platelet aggregation deficiency, homeostatic process disorder, tissue injury, migraine, inflammatory diseases (e.g., asthma), stroke, acute and chronic pain, hypovolemic shock, traumatic shock, reperfusion injury, Crohn's disease, ulcerative colitis, septic shock, multiple sclerosis, AIDS associated dementia, neurodegenerative diseases, neuron toxicity, Alzheimer's disease, chemical dependencies and addictions (e.g., dependencies on drugs, alcohol and nicotine), emesis, epilepsy, anxiety, psychosis, head trauma, adult respiratory distress syndrome (ARDS), morphine induced tolerance and withdrawal symptoms, inflammatory bowel disease, osteoarthritis, rheumatoid arthritis, dilated cardiomyopathy, acute spinal cord injury, Huntington's disease, Parkinson's disease, glaucoma, macular degeneration, diabetic neuropathy, diabetic ulcers and cancer in a mammal, including a human.
- More preferably, the pharmaceutical composition of the invention is useful in treating the conditions associated with platelet aggregation, homeostatic processes and tissue injury. The treatment of the condition of platelet aggregation has the effect on rapid hemostasis.
- The following examples further illustrate the present invention, but are not intended to limit the scope of the present invention. The modifications and substitutions known to those skilled in the art are still within the scope and spirit of the present invention.
- The cells of the mice macrophage cell line RAW 264.7 (under accession number CCRC 60001), which was obtained from Cell Culture Research Center, Food Industry Research and Development Institute, Hsinchu, Taiwan, R.O.C., were used for the test.
- The RAW 264.7 cells were incubated in a 96 well tissue culture plate (Falcon). After 24 hours, the cells were activated with Dulbecco's Modified Eagle Medium (DMEM, 2014, GibcoBRL) in the presence and absence of 100 ng/ml LPS, 100 U/ml IFN-γ and various concentrations (10 μM, 20 μM, 50 μM, 100 μM and 200 μM) of bismuth subgallate (Hwang et al., 1994, J. Biol. Chem. 269, p. 711-715). After 24 hours, 50 μl of the supernatant from each well was assayed for the presence of nitrite through the Saville modification of the Griess reaction (Green et al.,Analytical Biochem, 1982, 126:131-138). The results were represented by the means plus standard errors values (Mean±SE) of three repetitions.
- As shown in FIG. 1, the cells, which were not activated, by LPS and IFN-γ did not produce NO. In contrast, the cells, which were activated, by LPS and IFN-γ produced up to 65 μM of NO. Furthermore, those from cells incubated in the presence of bismuth subgallate showed a reduction in nitrite concentration, reflecting the reduction in NO production. The production of NO was inversely proportional to the increase in the concentration of bismuth subgallate.
- The effect of borneol on the inhibition of NO synthase was tested through the same experimental procedures as described in Example 1. Various concentrations of borneol (0 μM, 40 μM, 80 μM, 160 μM, 320 μM and 640 μM) were used to replace bismuth subgallate of Example 1. The results were represented by the mean values of three repetitions with standard errors (Mean±SE). As shown in FIG. 2, the production of NO was not significantly inhibited by the borneol.
- The effect of bismuth subgallate in combination with borneol on the inhibition of NO synthase was tested through the similar experimental procedures as described in Example 1. The following concentrations of Bismuth subgallate: 0 μM, 12.5 μM, 25 μM, 50 μM and 100 μM, were combined with the following concentrations of borneol: 0 μM, 10 μM, 20 μM and 40 μM, respectively, to obtain the combinations for the replacement of bismuth subgallate used in Example 1. The results were represented by the mean values of three repetitions with standard errors (Mean±SE). As shown in FIG. 3, the production of NO was significantly lowered by the treatment of the combination of bismuth subgallate with borneol. The effect of the combinations on the production of NO was more significant than that of bismuth subgallate only. In other words, a combination of bismuth subgallat with borneol exhibits a synergistic effect on inhibiting NO synthase.
Claims (24)
1. A method of inhibiting the production of nitric oxide synthases (NOS) in a subject, comprising administering to said subject in need thereof bismuth subgallate in an amount effective to inhibit the production of NOS.
2. The method of claim 1 , further comprising administering to said subject in need thereof borneol in an amount synergistically effective to inhibit the production of NOS.
3. A pharmaceutical composition for use in the inhibition of the production of NOS, which comprises a bismuth subgallate for use in the inhibition of the production of NOS in an effective amount sufficient to inhibit the production of NOS and a pharmaceutical acceptable carrier.
4. The pharmaceutical composition of claim 3 , wherein the amount of bismuth subgallate ranges from 0.05 to 40 percent by weight.
5. The pharmaceutical composition of claim 4 , wherein the amount of bismuth subgallate ranges from 1 to 20 percent by weight.
6. The pharmaceutical composition of claim 5 , wherein the amount of bismuth subgallate ranges from 2 to 10 percent by weight.
7. The pharmaceutical composition of claim 3 further comprising borneol, wherein the amounts of bismuth subgallate and borneol are synergistically effective for inhibiting the production of NOS.
8. The pharmaceutical composition of claim 7 , wherein the amount of bismuth subgallate and that of borneol range from 1 to 30 percent by weight and from 0.05 to 10 percent by weight, respectively.
9. The pharmaceutical composition of claim 8 , wherein the amount of bismuth subgallate and that of borneol range from 3 to 15 percent by weight and from 0. 1 to 5 percent by weight, respectively.
10. The pharmaceutical composition of claim 9 , wherein the amount of bismuth subgallate and that of borneol range from 4 to 8 percent by weight and from 0.5 to 1 percent by weight, respectively
11. The pharmaceutical composition of claim 3 , which further comprises another NOS inhibitor.
12. The pharmaceutical composition of claim 7 , which further comprises another NOS inhibitor.
13. The pharmaceutical composition of claim 3 , which is administered in topical, oral or parenteral route.
14. The pharmaceutical composition of claim 7 , which is administered in topical, oral or parenteral route.
15. A method of treating diseases in a subject in which nitric oxide production is implicated, comprising administering to said subject in need thereof an effective amount of bismuth subgallate.
16. The method of claim 15 , further comprising administering to said subject in need thereof a borneol in an amount synergistically effective to inhibit the production of NOS.
17. The method of claim 15 , wherein the diseases are selected from the group consisting of: platelet aggregation deficiency, homeostatic process disorder, tissue injury, migraine, inflammatory diseases, stroke, acute and chronic pain, hypovolemic shock, traumatic shock, reperfusion injury, Crohn's disease, ulcerative colitis, septic shock, multiple sclerosis, AIDS associated dementia, neurodegenerative diseases, neuron toxicity, Alzheimer's disease, chemical dependencies and addictions, emesis, epilepsy, anxiety, psychosis, head trauma, adult respiratory distress syndrome (ARDS), morphine induced tolerance and withdrawal symptoms, inflammatory bowel disease, osteoarthritis, rheumatoid arthritis ovulation, dilated cardiomyopathy, acute spinal cord injury, Huntington's disease, Parkinson's disease, glaucoma, macular degeneration, diabetic neuropathy, diabetic ulcers and cancer in a mammal.
18. The method of claim 15 , wherein the disease is platelet aggregation deficiency.
19. The method of claim 15 , wherein the disease is homeostatic process disorder.
20. The method of claim 18 , wherein the treatment of homeostatic process disorders has an effect on rapid hemostasis.
21. The method of claim 15 , wherein the disease is tissue injury.
22. The method of claim 15 , wherein the disease is inflammatory disease.
23. The method of claim 22 , wherein the inflammatory disease is asthma.
24. The method of claim 15 , wherein the disease is a diabetic ulcer.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/075,040 US20030040541A1 (en) | 2001-08-27 | 2002-02-12 | Use of bismuth subgallate in inhibition of production of nitric oxide synthase |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/940,405 US6514960B1 (en) | 2001-08-27 | 2001-08-27 | Use of bismuth subgallate in inhibition of production of nitric oxide synthase |
US10/075,040 US20030040541A1 (en) | 2001-08-27 | 2002-02-12 | Use of bismuth subgallate in inhibition of production of nitric oxide synthase |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/940,405 Continuation-In-Part US6514960B1 (en) | 2001-08-27 | 2001-08-27 | Use of bismuth subgallate in inhibition of production of nitric oxide synthase |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030040541A1 true US20030040541A1 (en) | 2003-02-27 |
Family
ID=25474768
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/940,405 Expired - Lifetime US6514960B1 (en) | 2001-08-27 | 2001-08-27 | Use of bismuth subgallate in inhibition of production of nitric oxide synthase |
US10/075,040 Abandoned US20030040541A1 (en) | 2001-08-27 | 2002-02-12 | Use of bismuth subgallate in inhibition of production of nitric oxide synthase |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/940,405 Expired - Lifetime US6514960B1 (en) | 2001-08-27 | 2001-08-27 | Use of bismuth subgallate in inhibition of production of nitric oxide synthase |
Country Status (6)
Country | Link |
---|---|
US (2) | US6514960B1 (en) |
EP (1) | EP1300148A3 (en) |
KR (1) | KR20030019060A (en) |
CN (1) | CN1401317A (en) |
CA (1) | CA2371393C (en) |
MY (1) | MY129637A (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070225364A1 (en) * | 2006-03-21 | 2007-09-27 | Hedonist Biochemical Technologies Co., Ltd. | Use of bismuth subgallate and borneol in treating melanoma |
CN101531589B (en) * | 2009-03-04 | 2012-07-04 | 西安近代化学研究所 | Gallic acid bismuth zirconium double metal salt, preparation method and application thereof |
CN105476982A (en) * | 2016-02-02 | 2016-04-13 | 张干 | New application of gallic acid |
CN110302196A (en) * | 2019-07-30 | 2019-10-08 | 安徽农业大学 | Polyphenol oxidase product treats diabetes |
CN110693902B (en) * | 2019-09-17 | 2021-08-31 | 深圳大学 | Application of bismuth potassium citrate in preparing medicament for preventing and treating neurodegenerative diseases |
CN112915095A (en) * | 2019-12-06 | 2021-06-08 | 罗胥恩 | Chronic wound healing composition and application thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2052698A1 (en) * | 1990-10-11 | 1992-04-12 | Roger G. Berlin | Treatment of peptic ulcer |
US5807885A (en) | 1993-08-12 | 1998-09-15 | Astra Aktiebolag | Amidine derivatives with nitric oxide synthetase activities |
RU2136661C1 (en) | 1993-10-21 | 1999-09-10 | Джи Ди Сирл энд Ко. | Amidino-derivatives, their use and pharmaceutical composition |
US5834002A (en) * | 1994-05-02 | 1998-11-10 | Josman Laboratories, Inc. | Chewing gum containing colloidal bismuth subcitrate |
WO1996021445A1 (en) | 1995-01-13 | 1996-07-18 | The General Hospital Corporation | Methods of inhibiting neurodegenerative diseases |
PT891332E (en) | 1996-03-29 | 2004-07-30 | Pfizer | 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES |
WO1998022118A1 (en) * | 1996-11-22 | 1998-05-28 | The Procter & Gamble Company | Compositions for the treatment of gastrointestinal disorders containing bismuth and nsaid |
TW460295B (en) | 1998-09-18 | 2001-10-21 | Hedonist Biochemical Technolog | Topical pharmaceutical compositions comprising bismuth subgallate and borneol for wound healing and preventing scarring and granulation |
MY143194A (en) * | 1998-10-05 | 2011-03-31 | Hedonist Biochemical Technolog | Topical pharmaceutical compositions for healing wounds |
PT1395289E (en) * | 2000-06-08 | 2011-03-16 | Sang Dr Christine | Treatment of neuropathic pain with a n-methyl-d-aspartate (nmda) receptor antagonists |
-
2001
- 2001-08-27 US US09/940,405 patent/US6514960B1/en not_active Expired - Lifetime
-
2002
- 2002-02-12 US US10/075,040 patent/US20030040541A1/en not_active Abandoned
- 2002-02-12 CA CA002371393A patent/CA2371393C/en not_active Expired - Lifetime
- 2002-02-28 KR KR1020020010929A patent/KR20030019060A/en not_active Application Discontinuation
- 2002-02-28 MY MYPI20020710A patent/MY129637A/en unknown
- 2002-03-14 EP EP02251821A patent/EP1300148A3/en not_active Withdrawn
- 2002-04-11 CN CN02106066A patent/CN1401317A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MY129637A (en) | 2007-04-30 |
EP1300148A2 (en) | 2003-04-09 |
CA2371393A1 (en) | 2003-02-27 |
EP1300148A3 (en) | 2003-05-21 |
CN1401317A (en) | 2003-03-12 |
CA2371393C (en) | 2008-09-23 |
KR20030019060A (en) | 2003-03-06 |
US6514960B1 (en) | 2003-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3880995A (en) | Treatment of arthritis with mycophenolic acid and derivatives | |
CN111388461B (en) | Blood sugar reducing composition and application thereof | |
EP2782563B1 (en) | Tetrahydrocannabivarin for use in the treatment of intestinal inflammatory diseases | |
JP2013507328A (en) | Compositions containing benzoic acid as an active component in combination with an organic acid preservative, and uses thereof | |
US6514960B1 (en) | Use of bismuth subgallate in inhibition of production of nitric oxide synthase | |
Hay et al. | Fluconazole in the management of patients with chronic mucocutaneous candidosis | |
NZ514536A (en) | Use of cetyl myristate and/or cetyl palmitate to treat asthma, chronic obstructive pulmonary disease and/or other respiratory difficulties | |
CN108685892A (en) | Purposes of the chlorogenic acid and combinations thereof in the drug for preparing treatment squamous cell carcinoma | |
Liu et al. | Scorpio and Scolopendra attenuate inflammation and articular damage in rats with collagen-induced arthritis | |
JP2003137776A (en) | Use of bismuth subgallate for inhibiting production of nitric oxide | |
Chou et al. | The anti-inflammatory and anti-hyperuricemic effects of Chinese herbal formula danggui-nian-tong-tang on acute gouty arthritis: a comparative study with indomethacin and allopurinol | |
EP3981422B1 (en) | Pharmaceutical composition containing lysozyme and use thereof | |
Fast et al. | Ecthyma gangrenosum. | |
ZWEIG et al. | Inhibition of sodium urate-induced rat hindpaw edema by colchicine derivatives: correlation with antimitotic activity | |
Paladino et al. | Resveratrol reverses the effect of TNF-α on inflammatory markers in a model of autoimmune uveitis | |
CN114796181A (en) | Application of leonurine in preparation of medicine for preventing and treating non-vascular dementia or infectious central nerve injury | |
GB2306321A (en) | The use of (+)-catechin in the treatment or prophylaxis of connective tissue disorders | |
US7037904B2 (en) | Use of N-acetyl-D-glucosamine in the manufacture of pharmaceutical useful for suppressing side-effect of radiotherapy and chemotherapy | |
CN111116395B (en) | Multi-iodo aromatic acid compound and application thereof in resisting adenovirus 7 | |
CN1041276C (en) | Drug for preventing common cold | |
Azelastine–Asthma Study Group | An evaluation of the efficacy and safety of azelastine in patients with chronic asthma | |
WO2021000417A1 (en) | Use of palmitoleic acid for preparing composition for preventing or treating inflammatory diseases | |
Al-Sa’ady et al. | EFFECT OF PARTIAL PURIFIED LOVASTATIN FROM ASPERGILLUS TERREUS A50 ON LIPID PROFILE AND LIVER ENZYMES IN VIVO | |
JPS58144317A (en) | Carcinostatic agent | |
CN114209683A (en) | Application of azelaic acid in preparation of medicine for treating inflammatory bowel disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: HEDONIST BIOCHEMICAL TECHNOLOGIES CO., LTD., TAIWA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TSAI, YING-CHIEH;WU, SZU-HUI;HSU, CHENG-SHENG;REEL/FRAME:012596/0349;SIGNING DATES FROM 20020124 TO 20020129 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |